PMID- 33372347
OWN - NLM
STAT- MEDLINE
DCOM- 20211213
LR  - 20211214
IS  - 1369-1600 (Electronic)
IS  - 1355-6215 (Linking)
VI  - 26
IP  - 4
DP  - 2021 Jul
TI  - Synergistic effects of MDMA and ethanol on behavior: Possible effects of ethanol 
      on dopamine D(2) -receptor-related signaling.
PG  - e13000
LID - 10.1111/adb.13000 [doi]
AB  - Polydrug abuse is common among drug abusers. In particular, psychostimulants are 
      often taken with ethanol, and the combination of 
      3,4-methylenedioxymethamphetamine (MDMA) and alcohol is one of the most common 
      forms of polydrug abuse. However, the mechanism by which these drugs influence 
      behavior remains unclear. The present study was designed to delineate the 
      mechanisms that underlie the effects of the interaction between MDMA and ethanol 
      on behavior in rodents. The combination of MDMA with ethanol enhanced their 
      locomotor-increasing, rewarding, and discriminative stimulus effects without 
      enhancing their effects on the release of dopamine from the nucleus accumbens in 
      rodents. In addition, ethanol potently enhanced locomotor activity produced by 
      the dopamine receptor agonist apomorphine in mice. In antagonism tests, the 
      dopamine D(1) -receptor antagonist SCH23390, but not the D(2) -receptor 
      antagonist haloperidol, completely suppressed hyperlocomotion induced by MDMA. 
      However, hyperlocomotion induced by the co-administration of MDMA and ethanol was 
      potently suppressed by haloperidol. These results suggest that the synergistic 
      effects of MDMA and ethanol are mediated through dopamine transmission, 
      especially through postsynaptical regulation of D(2) -receptor-mediated 
      functions.
CI  - (c) 2020 Society for the Study of Addiction.
FAU - Mori, Tomohisa
AU  - Mori T
AUID- ORCID: 0000-0002-7751-0231
AD  - Department of Pharmacology, Hoshi University School of Pharmacy and 
      Pharmaceutical Sciences, Tokyo, Japan.
AD  - Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical 
      Sciences, Tokyo, Japan.
FAU - Iwase, Yoshiyuki
AU  - Iwase Y
AD  - Department of Pharmacology, Hoshi University School of Pharmacy and 
      Pharmaceutical Sciences, Tokyo, Japan.
AD  - Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical 
      Sciences, Tokyo, Japan.
FAU - Uzawa, Naoki
AU  - Uzawa N
AD  - Department of Pharmacology, Hoshi University School of Pharmacy and 
      Pharmaceutical Sciences, Tokyo, Japan.
AD  - Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical 
      Sciences, Tokyo, Japan.
FAU - Takahashi, Yui
AU  - Takahashi Y
AD  - Department of Pharmacology, Hoshi University School of Pharmacy and 
      Pharmaceutical Sciences, Tokyo, Japan.
AD  - Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical 
      Sciences, Tokyo, Japan.
FAU - Mochizuki, Ayano
AU  - Mochizuki A
AD  - Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical 
      Sciences, Tokyo, Japan.
FAU - Fukase, Mika
AU  - Fukase M
AD  - Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical 
      Sciences, Tokyo, Japan.
FAU - Shibasaki, Masahiro
AU  - Shibasaki M
AD  - Department of Pharmacology, Hoshi University School of Pharmacy and 
      Pharmaceutical Sciences, Tokyo, Japan.
AD  - Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical 
      Sciences, Tokyo, Japan.
FAU - Suzuki, Tsutomu
AU  - Suzuki T
AD  - Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical 
      Sciences, Tokyo, Japan.
AD  - Institute of Drug Addiction Research, Hoshi University School of Pharmacy and 
      Pharmaceutical Sciences, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201228
PL  - United States
TA  - Addict Biol
JT  - Addiction biology
JID - 9604935
RN  - 0 (Benzazepines)
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Receptors, Dopamine D1)
RN  - 0 (Receptors, Dopamine D2)
RN  - 0 (SCH 23390)
RN  - 3K9958V90M (Ethanol)
RN  - J6292F8L3D (Haloperidol)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Benzazepines/pharmacology
MH  - Dopamine Antagonists/pharmacology
MH  - Ethanol/*pharmacology
MH  - Haloperidol/pharmacology
MH  - Male
MH  - Mice
MH  - Motor Activity/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Nucleus Accumbens/drug effects
MH  - Rats
MH  - Receptors, Dopamine D1
MH  - Receptors, Dopamine D2/*drug effects
OTO - NOTNLM
OT  - Akt
OT  - MDMA
OT  - alcohol
OT  - discriminative stimulus effects
OT  - locomotor activity
OT  - place preference
EDAT- 2020/12/30 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/12/29 06:06
PHST- 2020/12/01 00:00 [revised]
PHST- 2020/03/04 00:00 [received]
PHST- 2020/12/04 00:00 [accepted]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/12/29 06:06 [entrez]
AID - 10.1111/adb.13000 [doi]
PST - ppublish
SO  - Addict Biol. 2021 Jul;26(4):e13000. doi: 10.1111/adb.13000. Epub 2020 Dec 28.